Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED.

Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED.

Autoimmune Inner Ear Disease (AIED) is poorly characterized clinically, with no definitive laboratory test. All patients suspected of having AIED are given glucocorticoids during periods of acute hearing loss, however, only half initially respond, and still fewer respond over time.We hypothesized th...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Andrea Vambutas, James DeVoti, Elliot Goldofsky, Michael Gordon, Martin Lesser, Vincent Bonagura
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2009
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/ed85e191185243d5b815c4e3f5cc3dbf
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ed85e191185243d5b815c4e3f5cc3dbf
record_format dspace
spelling oai:doaj.org-article:ed85e191185243d5b815c4e3f5cc3dbf2021-11-25T06:22:58ZAlternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED.1932-620310.1371/journal.pone.0005293https://doaj.org/article/ed85e191185243d5b815c4e3f5cc3dbf2009-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19401759/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203Autoimmune Inner Ear Disease (AIED) is poorly characterized clinically, with no definitive laboratory test. All patients suspected of having AIED are given glucocorticoids during periods of acute hearing loss, however, only half initially respond, and still fewer respond over time.We hypothesized that AIED is a systemic autoimmune disease characterized by dysfunctional peripheral blood mononuclear cells (PBMC) responses to a unique cochlear antigen(s). To test this hypothesis, we examined end-stage AIED patients undergoing cochlear implant surgery and compared autologous perilymph stimulated PBMC from AIED patients to controls. We determined that autologous perilymph from AIED patients was unable to induce expression of a long membrane-bound Interleukin-1 Receptor Type II (mIL1R2) transcript in PBMC as compared with controls, despite similar expression of the short soluble IL1R2 (sIL1R2) transcript (p<0.05). IL1R2 is a molecular decoy that traps interleukin-1beta (IL-1beta) and does not initiate subsequent signaling events, thereby suppressing an inflammatory response. IL1R2 transcript length is regulated by alternate splicing, and the major inhibitory function is attributed to the full-length mIL1R2. In addition, IL1R2 expression is induced by dexamethasone.Separately, we prospectively examined patients with newer onset glucocorticoid-responsive AIED. Immediately prior to clinical treatment for acute deterioration of hearing thresholds, their PBMC demonstrated a robust induction of mIL1R2 in PBMC in response to dexamethasone in vitro that correlated with a clinical response to prednisone in vivo (p<0.0001) as measured by hearing restoration. In contrast, clinically steroid unresponsive patients demonstrated high basal levels of mIL1R2 in their PBMC and only minimally augmented expression in response to dexamethasone. Thus, induced expression of mIL1R2 appears to be a protective mechanism in hearing homeostasis and warrants further investigation in a large prospective clinical trial to determine if IL1R2 can be used as a specific biomarker for AIED.Andrea VambutasJames DeVotiElliot GoldofskyMichael GordonMartin LesserVincent BonaguraPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 4, Iss 4, p e5293 (2009)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Science
Q
spellingShingle Medicine
R
Science
Q
Andrea Vambutas
James DeVoti
Elliot Goldofsky
Michael Gordon
Martin Lesser
Vincent Bonagura
Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED.
description Autoimmune Inner Ear Disease (AIED) is poorly characterized clinically, with no definitive laboratory test. All patients suspected of having AIED are given glucocorticoids during periods of acute hearing loss, however, only half initially respond, and still fewer respond over time.We hypothesized that AIED is a systemic autoimmune disease characterized by dysfunctional peripheral blood mononuclear cells (PBMC) responses to a unique cochlear antigen(s). To test this hypothesis, we examined end-stage AIED patients undergoing cochlear implant surgery and compared autologous perilymph stimulated PBMC from AIED patients to controls. We determined that autologous perilymph from AIED patients was unable to induce expression of a long membrane-bound Interleukin-1 Receptor Type II (mIL1R2) transcript in PBMC as compared with controls, despite similar expression of the short soluble IL1R2 (sIL1R2) transcript (p<0.05). IL1R2 is a molecular decoy that traps interleukin-1beta (IL-1beta) and does not initiate subsequent signaling events, thereby suppressing an inflammatory response. IL1R2 transcript length is regulated by alternate splicing, and the major inhibitory function is attributed to the full-length mIL1R2. In addition, IL1R2 expression is induced by dexamethasone.Separately, we prospectively examined patients with newer onset glucocorticoid-responsive AIED. Immediately prior to clinical treatment for acute deterioration of hearing thresholds, their PBMC demonstrated a robust induction of mIL1R2 in PBMC in response to dexamethasone in vitro that correlated with a clinical response to prednisone in vivo (p<0.0001) as measured by hearing restoration. In contrast, clinically steroid unresponsive patients demonstrated high basal levels of mIL1R2 in their PBMC and only minimally augmented expression in response to dexamethasone. Thus, induced expression of mIL1R2 appears to be a protective mechanism in hearing homeostasis and warrants further investigation in a large prospective clinical trial to determine if IL1R2 can be used as a specific biomarker for AIED.
format article
author Andrea Vambutas
James DeVoti
Elliot Goldofsky
Michael Gordon
Martin Lesser
Vincent Bonagura
author_facet Andrea Vambutas
James DeVoti
Elliot Goldofsky
Michael Gordon
Martin Lesser
Vincent Bonagura
author_sort Andrea Vambutas
title Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED.
title_short Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED.
title_full Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED.
title_fullStr Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED.
title_full_unstemmed Alternate splicing of interleukin-1 receptor type II (IL1R2) in vitro correlates with clinical glucocorticoid responsiveness in patients with AIED.
title_sort alternate splicing of interleukin-1 receptor type ii (il1r2) in vitro correlates with clinical glucocorticoid responsiveness in patients with aied.
publisher Public Library of Science (PLoS)
publishDate 2009
url https://doaj.org/article/ed85e191185243d5b815c4e3f5cc3dbf
work_keys_str_mv AT andreavambutas alternatesplicingofinterleukin1receptortypeiiil1r2invitrocorrelateswithclinicalglucocorticoidresponsivenessinpatientswithaied
AT jamesdevoti alternatesplicingofinterleukin1receptortypeiiil1r2invitrocorrelateswithclinicalglucocorticoidresponsivenessinpatientswithaied
AT elliotgoldofsky alternatesplicingofinterleukin1receptortypeiiil1r2invitrocorrelateswithclinicalglucocorticoidresponsivenessinpatientswithaied
AT michaelgordon alternatesplicingofinterleukin1receptortypeiiil1r2invitrocorrelateswithclinicalglucocorticoidresponsivenessinpatientswithaied
AT martinlesser alternatesplicingofinterleukin1receptortypeiiil1r2invitrocorrelateswithclinicalglucocorticoidresponsivenessinpatientswithaied
AT vincentbonagura alternatesplicingofinterleukin1receptortypeiiil1r2invitrocorrelateswithclinicalglucocorticoidresponsivenessinpatientswithaied
_version_ 1718413836047876096

Ejemplares similares